Novel Combo Boosts Response in HER2 – Breast Cancer Novel Combo Boosts Response in HER2 – Breast Cancer
Neoadjuvant therapy with a novel combination of checkpoint inhibitor and PARP inhibitor showed benefit in all HER2-negative tumor subtypes.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Health | Hematology | HER2 | Neoadjuvant Therapy